EG382265 Inhibitors
EG382265 inhibitors are a class of chemical compounds specifically designed to inhibit the activity of the molecule EG382265, which is involved in regulating cellular processes, possibly through its role in enzyme activity or signaling pathways. While the exact function of EG382265 may vary depending on the biological context, it is likely engaged in facilitating or modulating interactions that influence key cellular mechanisms such as protein function, signal transduction, or metabolic regulation. By inhibiting EG382265, these compounds disrupt its ability to interact with substrates or binding partners, potentially altering the associated biochemical pathways. This inhibition serves as a useful approach for understanding the role of EG382265 in maintaining cellular processes and the effects of its activity on overall cellular function.
Structurally, EG382265 inhibitors are typically designed to bind to the active or allosteric sites of EG382265, preventing it from carrying out its normal biological functions. These inhibitors may work through competitive mechanisms, directly blocking the molecule's active site, or through non-competitive inhibition, which induces conformational changes that reduce its activity. The interaction between EG382265 inhibitors and their target molecule provides researchers with insight into the molecular pathways controlled by EG382265 and how its regulation impacts broader cellular systems. Studying these inhibitors allows scientists to explore how EG382265 contributes to processes like protein-protein interactions, enzymatic regulation, or intracellular signaling. Through this research, a deeper understanding of the intricate roles played by molecules like EG382265 in cellular regulation and biochemical pathways can be achieved, helping to clarify their significance in maintaining cellular homeostasis and functionality.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine, a nucleoside analogue, inhibits the AKT pathway by directly binding to the ATP-binding site of AKT. This disrupts AKT-mediated signaling cascades, leading to the downregulation of Cldn34c3 expression, as AKT is known to modulate its transcriptional activity in certain contexts. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 is a selective inhibitor of the TGF-β receptor ALK5. By blocking ALK5, SB-431542 disrupts the TGF-β signaling pathway, indirectly influencing Cldn34c3 expression, as TGF-β has been implicated in regulating gene expression in neural tissues. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, a key player in the PI3K/AKT pathway. By blocking PI3K activity, LY294002 disrupts the signaling cascades downstream, leading to indirect modulation of Cldn34c3 expression, as AKT, a downstream target of PI3K, is involved in the regulation of gene expression in neural tissues. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $272.00 | 2 | |
JNK Inhibitor VIII selectively inhibits the JNK signaling pathway. As the JNK pathway is implicated in various cellular processes, including transcriptional regulation, this inhibitor indirectly influences Cldn34c3 expression by disrupting the signaling cascades that may be involved in the modulation of gene expression in neural tissues. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of JNK. By inhibiting JNK, this compound disrupts the JNK signaling pathway, which can indirectly impact Cldn34c3 expression, as JNK is involved in the regulation of gene expression in various cellular contexts, including neural tissues where Cldn34c3 is expressed. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. By blocking PI3K, Wortmannin disrupts the PI3K/AKT pathway, indirectly influencing Cldn34c3 expression, as AKT, a downstream target of PI3K, is implicated in the regulation of gene expression in neural tissues. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, disrupting the MAPK/ERK pathway. Cldn34c3 expression is indirectly affected as this pathway can modulate transcriptional regulation. PD98059, by inhibiting MEK, disrupts the downstream signaling cascades, leading to altered gene expression patterns in the context of neural tissues where Cldn34c3 is expressed. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
SP2509 is a selective inhibitor of the TGF-β receptor ALK5. By blocking ALK5, SP2509 disrupts the TGF-β signaling pathway, indirectly influencing Cldn34c3 expression, as TGF-β has been implicated in regulating gene expression in neural tissues. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. By inhibiting p38 MAPK, this compound disrupts the p38 MAPK signaling pathway, indirectly influencing Cldn34c3 expression, as p38 MAPK is involved in the regulation of gene expression in various cellular contexts, including neural tissues where Cldn34c3 is expressed. | ||||||